Company intelligence / Profile preview

Wuhan Healthgen Biotechnology Corp.

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Wuhan Healthgen Biotechnology has completed Phase III trials for its plant-derived recombinant human serum albumin (OsrHSA) in patients with hypoalbuminemia due to liver cirrhosis. The product demonstrated non-inferior efficacy and safety compared to plasma-derived HSA. A new drug application will be submitted in 2024–2025 with expected market launch as early as next year. This would be the world’s first commercial plant-made recombinant human serum albumin approved for clinical use.

Therapeutic areas: EndocrinologyImmunologyOtherDermatologyGastroenterologyNeurologyInfectious Diseases
Modalities: Recombinant proteinsenzymespeptides
Industry: Biotech

Drug pipeline

5 assets

OsrHSA

4 more assets in the full pipeline.

Partnerships

Collaborations with biotechnology and pharmaceutical companies for custom expression services using their platform technologyNational Science and Technology Major Project for New Drug Development support from Chinese government agencies

Beyond the preview

Go deeper on Wuhan Healthgen Biotechnology Corp..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wuhan Healthgen Biotechnology Corp..